Epoetin beta
Also known as: EPO-beta, Epoetin beta, Epoetinum beta, NeoRecormon, Recormon, rhEPO, rHuEPO-beta
Source Epoetin beta at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Epoetin beta is a recombinant form of human erythropoietin used as a prescription erythropoiesis‑stimulating agent (ESA). It is administered intravenously or subcutaneously to treat anaemia associated with chronic kidney disease and chemotherapy‑induced anaemia. By stimulating red‑cell production, epoetin beta reduces the need for blood transfusions and can improve patients’ functional status, while its impact on overall survival remains uncertain.
Mechanism of Action
Epoetin beta mimics endogenous erythropoietin, binding to the erythropoietin receptor (EpoR) on erythroid progenitor cells in the bone marrow. This activates the JAK2‑STAT5 signalling cascade, promoting cell survival, proliferation and differentiation into mature red blood cells. Endogenous Epo synthesis is up‑regulated by hypoxia‑inducible factors (HIFs) in the kidneys; recombinant epoetin beta bypasses this regulation, directly driving erythropoiesis.
What the Research Shows
A meta‑analysis of three Japanese randomised, placebo‑controlled trials (511 patients) showed that epoetin beta halved the risk of transfusion (RR 0.47) without affecting overall survival (HR 1.00) or increasing thromboembolic events. A 2023 Cochrane network meta‑analysis of 62 new studies (9,237 participants) in chronic kidney disease found that epoetin beta probably reduces transfusion need (OR 0.19) but evidence is of low certainty; mortality effects were uncertain. Moderate‑certainty evidence indicated a higher odds of hypertension with epoetin beta (OR 2.17). Reviews note potential thromboembolic risk and highlight the importance of avoiding excessive haemoglobin targets to limit cardiovascular risk.
Reported Benefits
Clinical evidence indicates that epoetin beta can significantly lower the requirement for red‑cell transfusions in both chemotherapy‑induced and CKD‑related anaemia, which may lessen transfusion‑related complications and improve quality of life. The Japanese meta‑analysis reported no detrimental effect on overall survival, suggesting that appropriate use does not compromise longevity. By correcting anaemia, epoetin beta can also reduce fatigue and improve functional capacity in affected patients.
Limitations of the Evidence
The impact of epoetin beta on mortality and major cardiovascular events remains uncertain, with most evidence rated low to moderate certainty. While the Japanese trials did not show increased thromboembolism, other reviews caution about a possible rise in such events. The Cochrane review highlighted low certainty for transfusion benefit and unclear comparative effectiveness versus other ESAs. High haemoglobin targets (>13 g/dL) may elevate cardiovascular risk, and the optimal dosing strategy is not definitively established.
Safety Considerations
Moderate‑certainty data link epoetin beta to an increased risk of hypertension (approximately doubled odds versus placebo). Although the Japanese chemotherapy trials reported no rise in thromboembolic events, other sources note a potential for clotting complications, especially at higher doses. Careful monitoring of blood pressure and haemoglobin levels is essential to avoid overtreatment and associated cardiovascular risks. Patients with a history of thrombosis or uncontrolled hypertension should be evaluated before initiating therapy.
How It Is Administered
Epoetin beta is supplied as a sterile injectable solution for intravenous or subcutaneous administration. Dosing regimens vary according to indication, anaemia severity, and patient response, and are adjusted to maintain target haemoglobin levels while avoiding excessive rises. The drug is a prescription‑only biologic; preparation and injection must follow aseptic technique and manufacturer instructions.
Routes of Administration
Goals & Uses
- Treatment of anemia in chronic kidney diseaseHematology / NephrologyHigh
- Improvement of quality of lifePatient Reported OutcomesModerate
- Anemia in premature neonatesNeonatologyModerate
- Reduction of allogeneic blood transfusionsPerioperative MedicineModerate
- Anemia associated with myelodysplastic syndromesHematology / OncologyModerate
- Correction of anemiaHematologyHigh
- Chemotherapy-induced anemiaOncology / HematologyHigh
Contraindications
- Thrombotic risk or recent thrombotic eventCardiovascular / HematologicalModerate
- Cancer patients with curative intent receiving chemotherapyOncologyHigh
- Hypersensitivity to epoetin beta or excipientsAllergic / ImmunologicalHigh
- Active malignancy receiving chemotherapyOncologyModerate
- Known hypersensitivity to epoetin beta or any excipientsAllergyHigh
- Uncontrolled hypertensionCardiovascularHigh
- Pure red cell aplasia (PRCA) due to prior ESA therapyImmunologicalHigh
Adverse Effects
- Flu-like symptomsSystemic/ImmunologicalUncommon
- HypertensionCardiovascularCommonHigh blood pressure
- Injection site reactionsLocalCommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Thromboembolic eventsCardiovascularRare
- SeizuresNeurologicalRare
- Pure red cell aplasia (PRCA)Immunological / HematologicalRare
- Thrombotic/thromboembolic eventsCardiovascular / HematologicalUncommon
Drug Interactions
- Antihypertensive agentsModerate
- CyclosporineModerate
- Iron deficiencyModerate
- Iron supplementsModerate
- ACE inhibitorsLow
- ACE inhibitors / Angiotensin receptor blockersLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Patients with hemoglobin >10 g/dL at initiationHematologicalRelative
- Pediatric patientsAgeRelative
- LactationReproductiveRelative
- Pregnant or breastfeeding womenReproductiveRelative
- Cancer patients not receiving chemotherapyOncologicalRelative
Regulatory Status
- European UnionApprovedApproved: anemia due to chronic kidney disease, anemia secondary to chemotherapy, anemia in HIV infectionMarketed as NeoRecormon.
- United StatesUnapprovedEpoetin alfa is the FDA‑approved product; epoetin beta not submitted.
- United KingdomApprovedApproved: CKD‑related anemia, chemotherapy‑induced anemiaAligned with EU approval.
Approved in the European Union and several other jurisdictions; not approved in the United States where epoetin alfa is the marketed product.
Evidence & Sources
- Journal ArticleHighOhashi Y, et al.2013-01-01T00:00:00.000000Z
- Journal ArticleHighChung EY, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateJelkmann W2013-01-01T00:00:00.000000Z
- Journal ArticleModerateAgarwal N, Prchal JT2008-01-01T00:00:00.000000Z
- Journal ArticleModerateMimura I, Tanaka T, Nangaku M2015-01-01T00:00:00.000000Z
Frequently Asked Questions
What condition is epoetin beta primarily prescribed for?
Epoetin beta is approved to treat anaemia caused by chronic kidney disease or by chemotherapy in cancer patients, where low red‑cell counts result from insufficient endogenous erythropoietin.
Does epoetin beta improve survival in cancer patients?
A meta‑analysis of Japanese trials found no effect on overall survival compared with placebo, indicating that while transfusion needs are reduced, survival is not demonstrably improved.
What are the main safety concerns with epoetin beta?
The most consistent safety signal is an increased risk of hypertension. Potential thromboembolic events have been reported, especially at higher doses, and overly high haemoglobin targets may raise cardiovascular risk.
How is epoetin beta given and how often?
It is administered by injection, either intravenously or subcutaneously, on a schedule determined by the treating physician based on haemoglobin levels, usually weekly or every few weeks.
What is Epoetin beta?
Epoetin beta is a recombinant form of human erythropoietin used as a prescription erythropoiesis‑stimulating agent (ESA). It is administered intravenously or subcutaneously to treat anaemia associated with chronic kidney disease and chemotherapy‑induced anaemia. By stimulating red‑cell production, epoetin beta reduces the need for blood transfusions and can improve patients’ functional status, while its impact on overall survival remains uncertain.
What is Epoetin beta used for?
Epoetin beta is educationally associated with: Treatment of anemia in chronic kidney disease, Improvement of quality of life, Anemia in premature neonates, Reduction of allogeneic blood transfusions, Anemia associated with myelodysplastic syndromes, Correction of anemia, Chemotherapy-induced anemia. Educational only — not medical advice.
How is Epoetin beta administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Epoetin beta?
Reported adverse effects include: Flu-like symptoms, Hypertension, Injection site reactions, Headache, Thromboembolic events, Seizures, Pure red cell aplasia (PRCA), Thrombotic/thromboembolic events. This list is not exhaustive — consult a qualified clinician.
Who should avoid Epoetin beta?
Recorded contraindications: Thrombotic risk or recent thrombotic event, Cancer patients with curative intent receiving chemotherapy, Hypersensitivity to epoetin beta or excipients, Active malignancy receiving chemotherapy, Known hypersensitivity to epoetin beta or any excipients, Uncontrolled hypertension, Pure red cell aplasia (PRCA) due to prior ESA therapy. Consult a qualified clinician before use.